The Best of Swiss Web Award is an initiative of the simsa (Swiss Internet Industry Association) as well as Netzmedien AG with the aim of promoting transparency and quality standards in the Swiss web and ICT industry. In addition to the many web campaigns and applications represented, eve®, as a web-based platform for the planning, control and analysis of bioprocesses, was unique among the prizewinners.
The decisive factor in awarding eve® the prize was the identifiable added value for the customer, who gains clear competitive advantages thanks to the intelligent integration of workflows, devices, knowledge and big data in one platform.
"One of our target groups is the pharmaceutical industry which creates value from information and knowledge from bioprocess data in order to develop processes for new drugs as quickly as possible," explains Daniel Egger, member of the executive board and responsible for marketing and software development in the INFORS HT group, who accepted the prize on behalf of the development team. "In this regard, the insights gained from experiments are just as important as the precise control of bioprocesses which are continually optimized based on this knowledge. With the possibility of soft sensors, among others, eve® greatly accelerates easily integrated development processes."
eve® was developed in close collaboration with the Institute for 4D Technology (i4Ds) of the University of Applied Sciences and Arts Northwestern Switzerland, and thus represents another successful cooperation between Infors AG with a partner from the world of science.
More information about eve® can be found at www.infors-ht.com/eve
The decisive factor in awarding eve® the prize was the identifiable added value for the customer, who gains clear competitive advantages thanks to the intelligent integration of workflows, devices, knowledge and big data in one platform.
"One of our target groups is the pharmaceutical industry which creates value from information and knowledge from bioprocess data in order to develop processes for new drugs as quickly as possible," explains Daniel Egger, member of the executive board and responsible for marketing and software development in the INFORS HT group, who accepted the prize on behalf of the development team. "In this regard, the insights gained from experiments are just as important as the precise control of bioprocesses which are continually optimized based on this knowledge. With the possibility of soft sensors, among others, eve® greatly accelerates easily integrated development processes."
eve® was developed in close collaboration with the Institute for 4D Technology (i4Ds) of the University of Applied Sciences and Arts Northwestern Switzerland, and thus represents another successful cooperation between Infors AG with a partner from the world of science.
More information about eve® can be found at www.infors-ht.com/eve
